Q317 · How should I handle medicines returned by…

Q317 · Category G: Quality management and compliance systems (Q301–Q350)

Returns are a high-risk area and must be governed by a strict SOP. First, all returned drugs must be identified immediately and quarantined in a dedicated, secure returns area to prevent them from inadvertently re-entering saleable stock. An authorised member of the quality department must then carefully assess the returned drugs to determine their final disposition. Only if very strict conditions are met may drugs be considered for return to saleable stock. These conditions include the drugs remaining in their original, unopened packaging; storage conditions having been maintained throughout (for example, with evidence that the cold chain was not interrupted); sufficient remaining shelf life; and inspection and approval by a qualified person. Any drugs that do not meet these conditions must be destroyed.

📘 Regulatory basis

Chapter 6, “Complaints, Returns, Suspected Falsified Medicinal Products and Medicinal Product Recalls”, of the Good Distribution Practice (GDP) for Medicinal Products sets out detailed requirements for handling returns. It expressly states that returned medicines must undergo a risk assessment before their disposition is decided, and that the conditions for returning them to stock for sale are very stringent.

📗 Drew Tang's recommendations

Our core recommendation is to take the most conservative approach to returns: “When in doubt, destroy.” Reselling returned medicines carries a very high risk, as it is difficult to be absolutely certain about the storage conditions they were kept in after leaving your warehouse. It is vital to keep clear records of the receipt, assessment and disposal of returns. Strictly reserve decisions on handling returns to the quality department, so that sales pressures do not affect quality judgements.

📕 Risk notice

Incorrectly returning non-conforming returned medicines to stock for sale poses an extremely serious quality and safety risk. If the medicines have deteriorated or have been stored improperly, they could harm patients. If discovered by regulators, this will be regarded as a serious GDP breach and may result in your licence being suspended or revoked immediately.

Plan Your Hong Kong Pharmaceutical Licensing Project with Drew Tang

Business Manager Tang Shangyong (Drew Tang) will review your products, operating model, licence type and preparation requirements with you one-to-one. The precise service scope is confirmed in writing; pharmaceutical duties are carried out by legally qualified personnel, and approvals are determined by the competent authorities.

How should I handle medicines returned by customers? Can returned medicines be sold again?

Plan Your Hong Kong Pharmaceutical Licensing Project with Drew Tang